Rigel Pharmaceuticals (RIGL) announced that it has entered into a settlement agreement with Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA resolving patent litigation related to Rigel’s product Tavalisse. The litigation resulted from submission by Annora of an Abbreviated New Drug Application to the U.S. FDA seeking approval to market a generic version of Tavalisse in the United States. Under the terms of the settlement agreement, Annora will have a license to sell its generic product in Q2 2032 or earlier under certain circumstances. In accordance with the agreement, the parties terminated all ongoing litigation between Rigel and Annora regarding Tavalisse patents pending in New Jersey.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RIGL:
- Rigel Pharmaceuticals Appoints Dr. Frohlich to Board
- Rigel Pharmaceuticals price target raised to $55 from $49 at Citi
- Rigel Pharmaceuticals Implements 1-for-10 Reverse Stock Split: Balancing Nasdaq Compliance and Investor Appeal
- Rigel Pharmaceuticals Reports Record Sales and Strategic Growth
- Rigel Pharmaceuticals price target raised to $24 from $20 at B. Riley